SCHEMBL23488290

SCHEMBL23488290

COc1cc(C(=O)OC[C@H]2OC(C)[C@H](O)[C@@H](O)[C@H]2O)cc(Cl)c1NC(=O)c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.42
TAS1R3 Q7RTX0 1/20 0.41
TAS1R1 Q7RTX1 1/20 0.41
TAS1R2 Q8TE23 1/20 0.41
XDH P47989 2/20 0.41
MAPK1 P28482 2/20 0.41
MAPT P10636 1/20 0.41
AHR P35869 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.38
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.38
TYMP P19971 1/20 0.37
SELL P14151 1/20 0.37
SELP P16109 1/20 0.37
KDM4E B2RXH2 1/20 0.37
HSD17B10 Q99714 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23488466 0.90 TDP1 (0.47) TDP1TAS1R3TAS1R1TAS1R2XDH
SCHEMBL23488477 0.87 TAS1R3 (0.40) TDP1TAS1R3TAS1R1TAS1R2XDH
SCHEMBL23488280 0.85 MAPT (0.48) TDP1XDHMAPK1MAPTAHR
SCHEMBL23488423 0.84 XDH (0.46) TDP1TAS1R3TAS1R1TAS1R2XDH
SCHEMBL23488431 0.83 TDP1 (0.43) TDP1XDHMAPTALDH1A1TYMP
SCHEMBL23488272 0.83 TDP1 (0.43) TDP1XDHMAPTALDH1A1TYMP
SCHEMBL23488693 0.80 KDM4E (0.46) TDP1XDHMAPK1MAPTSMN1; SMN2
SCHEMBL23488129 0.80 KDM4E (0.46) TDP1XDHMAPK1MAPTSMN1; SMN2
SCHEMBL23488247 0.78 RAB9A (0.57) MAPTSMN1; SMN2KMT2AMEN1ALDH1A1
SCHEMBL12886328 0.78 ALDH1A1 (0.50) TDP1MAPK1ALDH1A1LMNATYMP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210170033-A1 NOVEL CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN SANOFI (FR) 2021-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210170033-A1 NOVEL CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN GPR119, SLC2A8, SLC2A4 TDP1 4093/4885TAS1R3 1195/4885TAS1R1 967/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.